10-QPeriod: Q2 FY2004

QUEST DIAGNOSTICS INC Quarterly Report for Q2 Ended Jun 30, 2004

Filed July 30, 2004For Securities:DGX

Summary

Quest Diagnostics Incorporated (DGX) reported solid financial performance for the quarter ended June 30, 2004, with net revenues increasing by 6.4% year-over-year to $1.30 billion, and net income growing to $126.8 million from $120.4 million in the prior year period. For the first six months of 2004, net revenues saw a 10.4% increase to $2.55 billion, and net income rose to $243 million from $208.4 million in the comparable period of 2003. This growth was driven by a combination of increased testing volumes and a higher average revenue per requisition, attributed to a favorable shift in test mix towards higher-value and gene-based testing, as well as efficiency gains from Six Sigma and standardization initiatives. The company also provided updates on its financial condition, including a robust operating cash flow of $318 million for the first six months of 2004. Quest Diagnostics also actively managed its capital structure, completing significant debt refinancing in April 2004, including a new $500 million revolving credit facility. Furthermore, the company continued its commitment to returning value to shareholders through share repurchases, having spent $271 million on treasury stock purchases in the first six months of the year, and initiated a quarterly cash dividend. Despite some non-recurring charges related to CEO succession and debt refinancing costs, the overall financial health appears strong, with management expressing confidence in their ability to fund future growth and operations.

Key Highlights

  • 1Net revenues for the quarter increased 6.4% to $1.30 billion, driven by higher volumes and average revenue per requisition.
  • 2Net income for the quarter rose to $126.8 million ($1.20 diluted EPS) from $120.4 million ($1.12 diluted EPS) in the prior year.
  • 3Year-to-date (six months) net revenues grew 10.4% to $2.55 billion, with net income increasing to $243 million ($2.30 diluted EPS) from $208.4 million ($1.98 diluted EPS).
  • 4Operating income margin improved to 17.2% for the six-month period, up from 16.5% in the prior year, reflecting revenue growth and efficiency gains.
  • 5Strong operating cash flow of $318 million was generated in the first six months of 2004.
  • 6Significant debt refinancing occurred in April 2004, including a new $500 million senior unsecured revolving credit facility.
  • 7The company repurchased approximately $271 million of its common stock in the first six months of 2004 and declared quarterly dividends.

Frequently Asked Questions

Revenue growth was driven by a 6.4% increase in net revenues to $1.30 billion. This was primarily due to improvements in testing volumes (up 2.1%) and an increase in average revenue per requisition (up 3.7%), which benefited from a favorable shift in test mix towards higher-value services like gene-based testing and increases in the number of tests ordered per requisition.

Total operating costs and expenses increased, but as a percentage of net revenues, Cost of Services remained stable at 57.6% for the quarter, and Selling, General, and Administrative expenses decreased to 23.7% from 24.3%. Efficiency gains from Six Sigma and standardization initiatives, along with improved billing and collection processes, helped offset increased investments in operations and employee compensation.

Quest Diagnostics completed significant debt refinancing in April 2004, including a new $500 million revolving credit facility, enhancing its liquidity. The company generated $318 million in cash flow from operations in the first six months of 2004, ending the period with $137.8 million in cash and cash equivalents. While there were $2.9 million in charges related to debt refinancing costs, overall debt levels and liquidity appear well-managed.

Quest Diagnostics continued its share repurchase program, buying back approximately $271 million of its common stock in the first six months of 2004. The company also initiated a quarterly cash dividend of $0.15 per share, reflecting a commitment to shareholder returns.